Share chart uniQure
Extended chart
Simple chart
About uniQure
uniQure NV - компания, специализирующаяся на генной терапии. Он разрабатывает лечение и платформу для пациентов, страдающих генетическими и другими серьезными заболеваниями. Его продукты и услуги ориентированы на гемофилию, болезнь Хантингтона и сердечно-сосудистые заболевания. В сотрудничестве с Bristol Myers-Squibb компания сосредоточена на разработке линейки генных методов лечения сердечно-сосудистых заболеваний.| IPO date | 2007-06-20 |
|---|---|
| ISIN | NL0010696654 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Див.доход ао | 0 |
| Сайт | http://www.uniqure.com |
| Цена ао | 14.36 |
| Change price per day: | 0% (14.36) |
|---|---|
| Change price per week: | +2.28% (14.04) |
| Change price per month: | +25.09% (11.48) |
| Change price per 3 month: | -17.23% (17.35) |
| Change price per half year: | +188.64% (4.975) |
| Change price per year: | +165.43% (5.41) |
| Change price per 3 year: | -13.55% (16.61) |
| Change price per 5 year: | -64.32% (40.25) |
| Change price per 10 year: | -24.3% (18.97) |
| Change price per year to date: | -16.61% (17.22) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Institutions | Volume | Share, % |
|---|---|---|
| Nantahala Capital Management, LLC | 5916054 | 12.37 |
| Vestal Point Capital, LP | 3925000 | 8.2 |
| State Street Corporation | 3478872 | 7.27 |
| Blackrock Inc. | 1836696 | 3.84 |
| Morgan Stanley | 1759818 | 3.68 |
| 683 Capital Management LLC | 1693000 | 3.54 |
| Orbimed Advisors LLC. | 1347900 | 2.82 |
| Pictet Asset Management Holding SA | 1324246 | 2.77 |
| International Biotechnology Trust PLC | 1241500 | 2.6 |
| Schroder Investment Management Group | 1241500 | 2.6 |
| ETF | Share, % | Profitability for 1 year, % | Dividends, % |
|---|---|---|---|
| Virtus LifeSci Biotech Clinical Trials ETF | 0.80858 | 63.04 | 0.33 |
| Global X Genomics & Biotechnology ETF | 0.412 | 2.58 | 0.15585 |
| ProShares UltraShort Nasdaq Biotechnology | 0.35 | -40.36 | 1.76 |
| Avantis U.S Small Cap Equity ETF | 0.02943 | 27.77 | 1.68271 |
| Invesco Nasdaq Biotechnology ETF | 0.02658 | 28.58 | 0.8565 |
| Principal Healthcare Innovators ETF | 0.02271 | 618.5 | 0.8416 |
| Future Tech ETF | 0.02271 | 426.34 | 0.8416 |
| Invesco FTSE RAFI US 1500 Small-Mid ETF | 0.02226 | 17.58 | 1.75869 |
| ProShares Ultra Nasdaq Biotechnology | 0.01858 | 51.7 | 0.85651 |
Schwab U.S. Small-Cap ETF
|
0.00652 | 17.47 | 1.51433 |
| Avantis U.S. Equity ETF | 0.00076 | 23.04 | 1.59151 |
Schwab U.S. Broad Market ETF
|
0.00043 | 24.86 | 1.43354 |
| 0.14 | 105.09 | 1.14 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Mr. Matthew Craig Kapusta | CEO & Executive Director | 1.16M | 1972 (53 years) |
| Mr. Christian Klemt | CFO, Principal Financial Officer & GM of Amsterdam Site | 566.36k | 1973 (52 years) |
| Prof. Hugo Katus | Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany | N/A | |
| Ms. Maria E. Cantor | Chief Corporate Affairs Officer | 491.12k | 1968 (57 years) |
| Dr. Tamara Tugal Ph.D., MBA | Business Development Director | N/A | |
| Dr. Jeannette Potts J.D., Ph.D. | Chief Legal & Compliance Officer and Corporate Secretary | N/A | 1962 (63 years) |
| Mr. Richard Porter Ph.D. | Chief Business & Scientific Officer | N/A | 1968 (57 years) |
| Dr. Amin Abujoub Ph.D. | Chief Technical Operations | N/A | |
| Dr. Walid Abi-Saab M.D. | Chief Medical Officer | 1965 (60 years) | |
| Eileen Sawyer | Vice President of Global Medical Affairs |
Address: Netherlands, Amsterdam BP, Paasheuvelweg 25a - open in Google maps, open in Yandex maps
Website: http://www.uniqure.com
Website: http://www.uniqure.com
